InvestorsHub Logo
Followers 30
Posts 4277
Boards Moderated 0
Alias Born 03/20/2011

Re: FACT-MASTER post# 67

Thursday, 11/17/2022 2:04:30 PM

Thursday, November 17, 2022 2:04:30 PM

Post# of 154
Thanks it's here in black and white:

https://ca.finance.yahoo.com/news/immatics-announces-third-quarter-2022-120000183.html

Cohort B – The first patient in the Phase 1b expansion cohort B was treated with IMA203 in combination with the PD-1 immune checkpoint inhibitor nivolumab in May 2022. Patients will be treated at RP2D.

Nivolumab / Opdivo = Bristol Myers Squibb


https://www.opdivo.com/
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IMTX News